Subscribe
The latest psychology and neuroscience discoveries.
My Account
  • Mental Health
  • Social Psychology
  • Cognitive Science
  • Psychopharmacology
  • Neuroscience
  • About
No Result
View All Result
PsyPost
PsyPost
No Result
View All Result
Home Exclusive Psychopharmacology

Brief depression questionnaires could lead to unnecessary antidepressant prescriptions

by University of California at Davis
September 29, 2014
in Psychopharmacology
Photo credit: Justin Ling (Creative Commons)

Photo credit: Justin Ling (Creative Commons)

Share on TwitterShare on Facebook
Stay on top of the latest psychology findings: Subscribe now!

Known as “brief depression symptom measures,” the self-administered questionnaires are used in primary care settings to determine the frequency and severity of depression symptoms among patients. Several questionnaires have been developed to help reduce untreated depression, a serious mental illness that can jeopardize relationships, employment and quality of life and increase the risks of heart disease, drug abuse and suicide.

The UC Davis team was concerned that the questionnaires might lead to prescriptions for antidepressant medication being given to those who aren’t depressed. Antidepressants are effective in treating moderate-to-severe depression but can have significant side effects, including sexual dysfunction, sedation and anxiety. They also have to be taken over several months to be effective.

“It is important to treat depression, but equally important to make sure those who get treatment actually need it,” said Anthony Jerant, professor of family and community medicine at UC Davis and lead author of the study.

The exploratory study included 595 patients of primary care offices affiliated with Kaiser Permanente in Sacramento, San Francisco VA Medical Center, Sutter Medical Group in Sacramento, UC Davis, UC San Francisco and VA Northern California Healthcare System.

Patients selected for the study were considered at low risk for depression and therefore poor candidates for antidepressants, based on results of a widely-employed brief screening tool known as the Patient Health Questionnaire – 9 (PHQ-9), which was administered by the research team. The screener, which includes questions about changes in sleep, concentration, energy and appetite, was completed the same day the patients had appointments to see their primary care physicians, who were unaware their patients had completed the PHQ-9.

Based on a review of medical records, the patients were divided into two groups: those who were asked during their doctors’ office visits to complete brief depression symptom questionnaires, besides the one administered by the researchers, and those who were not. The groups were compared in terms of rates of depression diagnoses and prescriptions for antidepressants received from their physicians.

Of the 545 patients who did not complete brief depression questionnaires during their doctors’ office visits, 10.5 percent were diagnosed with depression and 3.8 percent were prescribed antidepressants.

Of the 50 patients who completed brief depression questionnaires during their doctors’ office visits, 20 percent were diagnosed with depression and 12 percent were prescribed antidepressants.

Jerant said the study highlights the need for research to determine the best ways to apply brief depression questionnaires in daily practice, as use of the screeners tripled the likelihood that patients in the study who were not apt to be depressed would receive depression treatment.

Part of the problem could be in how questionnaire results are interpreted, Jerant said. Depression symptoms such as insomnia, fatigue and poor concentration are associated with many health conditions.

“The questionnaires aren’t diagnostic in the sense that there’s a certain score that means the patient definitely does or does not have depression,” Jerant said. “Formal interviews are required to help doctors decide whether a patient’s fatigue, for instance, is caused by depression. That fatigue could also be due to chronic lung or heart disease. It could also be due to an adjustment disorder that is usually transient and isn’t likely to respond to antidepressants. We need to give providers good guidance on how to use brief symptom measures in evaluating patients and making treatment decisions.”

Additional study researchers were senior author Peter Franks and co-authors Richard Kravitz, Erik Fernandez y Garcia, Camille Cipri, Denyse Nishio, Anca Knoepfler, M. Kaleo Wooddell and Victor Baquero of UC Davis, and Mitchell Feldman of UC San Francisco. Their research was supported by grant 1R01MH079387 from the National Institute of Mental Health.

A copy of the study, titled “Potential Antidepressant Overtreatment Associated with Office Use of Brief Depression Symptom Measures,” is available online at http://www.jabfm.org/content/27/5/611.abstract.

TweetSendScanShareSendPinShareShareShareShareShare

RELATED

A surprising body part might provide key insights into schizophrenia risk
Addiction

Neuroscientists shed new light on how heroin disrupts prefrontal brain function

July 11, 2025

After heroin exposure and abstinence, mice showed reduced prefrontal brain activity during social interaction but heightened responses to drug-related cues, suggesting heroin disrupts normal brain function in ways that may contribute to social withdrawal and relapse risk.

Read moreDetails
Loss of empathy in frontotemporal dementia traced to weakened brain signals
ADHD

Adults treated with psychostimulants for ADHD show increased brain surface complexity, study finds

July 10, 2025

Researchers have discovered that long-term psychostimulant use in adults with ADHD is associated with increased brain surface complexity, yet these anatomical differences appear unrelated to clinical outcomes, according to a study using high-resolution MRI data from UCLA.

Read moreDetails
Little-known psychedelic found to have a fascinating effect on cognitive flexibility after just a single dose
Psychedelic Drugs

Fascinating new advances in psychedelic science reveal how they may heal the mind

July 9, 2025

A series of recent studies has begun to map the specific neural, cognitive, and emotional processes that psychedelics influence—often in ways that challenge long-held assumptions

Read moreDetails
Ketamine repairs reward circuitry to reverse stress-induced anhedonia
Depression

Ketamine repairs reward circuitry to reverse stress-induced anhedonia

July 9, 2025

New research shows a single low, non-anesthetic dose of ketamine revived pleasure seeking in chronically stressed mice by restoring weakened excitatory synapses onto nucleus accumbens dopamine D1 neurons, pinpointing a circuit mechanism for the drug’s rapid antidepressant effect.

Read moreDetails
Use of mescaline may facilitate unintended improvements in several psychiatric conditions, study suggests
Ayahuasca

Many ayahuasca users report challenging experiences—yet some are linked to better mental health

July 4, 2025

Are challenging ayahuasca experiences always harmful? Not necessarily, finds a new global survey. While some effects predict poorer mental health, others like visual distortions are linked to positive outcomes, highlighting the crucial role of context and individual vulnerability.

Read moreDetails
Taking medicinal cannabis oil for insomnia does not impair cognition on the following day
Cannabis

Cannabis oil might help with drug-resistant epilepsy, study suggests

July 2, 2025

Nineteen patients with drug-resistant epilepsy experienced seizure freedom after cannabis oil treatment, with a median seizure-free duration of 245 days. Five remained seizure-free for over a year, and most reported improved quality of life and reduced seizure frequency.

Read moreDetails
Psychedelic compound blurs boundary between self and others in the brain, study finds
Ayahuasca

Psychedelic compound blurs boundary between self and others in the brain, study finds

July 2, 2025

A recent study found that a DMT/harmine formulation blurs the brain’s distinction between self and other faces, disrupting self-referential processing while preserving recognition of familiar faces, suggesting a neural basis for psychedelic-induced ego dissolution.

Read moreDetails
Researchers identify neural mechanism behind memory prioritization
MDMA

New study reveals how MDMA rewires serotonin and oxytocin systems in the brain

June 30, 2025

Researchers found that MDMA reduces anxiety and enhances social behavior in zebrafish by altering key neurochemical systems. The drug suppressed serotonin signaling, boosted oxytocin receptor expression, and modulated brain signaling proteins involved in emotional regulation.

Read moreDetails

SUBSCRIBE

Go Ad-Free! Click here to subscribe to PsyPost and support independent science journalism!

STAY CONNECTED

LATEST

Neuroscientists shed new light on how heroin disrupts prefrontal brain function

New research identifies four distinct health pathways linked to Alzheimer’s disease

A surprising body part might provide key insights into schizophrenia risk

Religious belief linked to lower anxiety and better sleep in Israeli Druze study

A common vegetable may counteract brain changes linked to obesity

Massive psychology study reveals disturbing truths about Machiavellian leaders

Dementia: Your lifetime risk may be far greater than previously thought

Psychopathic tendencies may be associated with specific hormonal patterns

         
       
  • Contact us
  • Privacy policy
  • Terms and Conditions
[Do not sell my information]

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

Subscribe
  • My Account
  • Cognitive Science Research
  • Mental Health Research
  • Social Psychology Research
  • Drug Research
  • Relationship Research
  • About PsyPost
  • Contact
  • Privacy Policy